Hepatocellular carcinoma is the fifth most common cancer worldwide and the second most lethal, following lung cancer. Currently applied therapeutic practices rely on surgical resection, chemotherapy and radiotherapy, or a combination thereof. These treatment options are associated with extreme adversities, and risk/benefit ratios do not always work in patients’ favor. Anomalies of the epigenome lie at the epicenter of aberrant molecular mechanisms by which the disease develops and progresses. Modulation of these anomalous events poses a promising prospect for alternative treatment options, with an abundance of felicitous results reported in recent years. Herein, the most recent epigenetic modulators in hepatocellular carcinoma are recapitulated on.

中文翻译：

---

肝遗传学：肝细胞癌的表观遗传调节剂和潜在疗法的综述。

肝细胞癌是继肺癌之后全球第五大最常见的癌症和第二大致命的癌症。当前应用的治疗实践依赖于手术切除，化学疗法和放射疗法或其组合。这些治疗选择与极端逆境有关，风险/收益比并不总是对患者有利。表观基因组异常位于疾病发展和进展的异常分子机制的中心。对这些异常事件的调节为替代治疗方案的发展带来了广阔的前景，近年来报道了许多可喜的成果。在此，概述肝细胞癌中最新的表观遗传调节剂。